✦ LIBER ✦

Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2

✍ Scribed by Escudier, B; Farace, F; Angevin, E; Charpentier, F; Nitenberg, G; Triebel, F; Hercend, T

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival characteristics of metastatic r

✍ Deric D. Schoof; Yasunori Terashima; Steven Batter; Linda Douville; Jerome P. Ri 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 720 KB

Combination of lymphokine-activated kill

✍ T. FUJIOKA; K. NOMURA; M. HASEGAWA; K. ISHIKURA; T. KUBO 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 1010 KB

Levels of soluble interleukin-2 receptor

✍ Elisabeth Paietta; David L. Nelson; Janet Andersen; Janice P. Dutcher; Peter H. 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 428 KB

Non-cytotoxic CD4 tumourinfiltrating lym

✍ C. Mathiot; N. Thiounn; E. Tartour; T. Flam; C. Peyret; I. Joyeux; M. Zerbib; M. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Tolerance and effectiveness of recombina

✍ Stahel, R.A.; Sculier, J.P.; Jost, L.M.; Delforge, A.; Bron, D.; Gmür, J.; Oelz, 📂 Article 📅 1989 🏛 Elsevier Science ⚖ 725 KB

Correlation between clinical response to

✍ Bain, C; Merrouche, Y; Puisieux, I; Blay, J-Y; Negrier, S; Bonadona, V; Lasset, 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 555 KB